Neurodegenerative Diseases Therapeutics Market by Indication and Geography - Forecast and Analysis 2022-2026

Published: Apr 2022 Pages: 141 SKU: IRTNTR73294

Based on Technavio's market sizing methodology, the neurodegenerative diseases therapeutics market size is predicted to surge by USD 19.74 billion from 2021 to 2026 at a CAGR of 7.98%.

This neurodegenerative diseases therapeutics market research report extensively covers market segmentations by the following:

  • Indication - Multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, and others
  • Geography - North America, Europe, Asia, and Rest of World (ROW)

This neurodegenerative diseases therapeutics industry report further provides detailed data on several market vendors, including AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., Biogen Inc., F. Hoffmann La Roche Ltd., H Lundbeck AS, Mitsubishi Chemical Holdings Corp., Novartis AG, Sanofi, and Teva Pharmaceutical Industries Ltd. among others. One of the key highlights of this report is the post COVID-19 impact analysis on the market, which will help companies evaluate their business approaches for the future.

What will the Neurodegenerative Diseases Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Neurodegenerative Diseases Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Neurodegenerative Diseases Therapeutics Market: Key Drivers, Trends, and Challenges

The strong drug development pipeline is notably driving the neurodegenerative diseases therapeutics market growth, although factors such as lack of disease-modifying therapies may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the neurodegenerative diseases therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Neurodegenerative Diseases Therapeutics Market Driver

One of the key factors driving the global neurodegenerative diseases therapeutics market growth is the strong drug development pipeline owing to the increasing incidence of neurogenerative diseases. For instance, as per the Centers for Disease Control and Prevention (CDC), in 2021, Alzheimer's disease affected around 6.2 million people in the US and is expected to nearly triple to 14 million people by 2060. Thus, there are several drugs in the pipeline due to the increase in the R&D. For instance, ABT-SLV187 by AbbVie is in phase III. APL-130277 for parkinsons disease by Sunovion is also in phase III. The introduction of these drugs in the market will drive the market growth in the forecast period.

Key Neurodegenerative Diseases Therapeutics Market Trend

Increase in the aging population, with declining fertility and increasing longevity, is one of the key neurodegenerative diseases therapeutics market trends that is expected to impact the industry positively in the forecast period. According to WHO, between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. Medicine has prolonged the morbidity phase, which has, resulted in an increase in the risk of developing neurological disorders such as alzheimers disease and parkinsons disease. In underdeveloped regions such as Sub-Saharan Africa, neurological disorders are commonly found in the elderly; degenerative diseases such as dementia and PD were the most common diseases reported in the region. Such factors will further support the market growth in the coming years.

Key Neurodegenerative Diseases Therapeutics Market Challenge

One of the key challenges to the global neurodegenerative diseases therapeutics market growth is the lack of disease-modifying therapies. The prevalence of neurodegenerative diseases is rising with the increase in the aging population globally. For instance, AD doubles in frequency every five years after 65 years of age and affects up to 50% of those over 85 years of age. However, at present, there are no disease-modifying therapies that work by impacting the disease processes, for some neurodegenerative diseases. Although diseases such as parkinsons and Alzheimers have drugs that can provide symptomatic relief, some neurodegenerative diseases such as huntingtons disease, which is caused due to a mutation in the huntingtin gene, have no approved therapy for treatment. Such factors may limit the market growth in the forecast years.

This neurodegenerative diseases therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global neurodegenerative disease therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the neurodegenerative diseases therapeutics market during the forecast period.

Who are the Major Neurodegenerative Diseases Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • AB Science SA
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Biogen Inc.
  • F. Hoffmann La Roche Ltd.
  • H Lundbeck AS
  • Mitsubishi Chemical Holdings Corp.
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

 

This statistical study of the neurodegenerative diseases therapeutics market encompasses successful business strategies deployed by the key vendors. The neurodegenerative diseases therapeutics market is concentrated and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

  • AB Science SA - The company offers neurodegenerative diseases therapeutics named Masitinib phase 3. 
  • AB Science SA - Through the unified segment, the company manufactures and distributes medical drugs and equipment in various parts of the world. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The neurodegenerative diseases therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Neurodegenerative Diseases Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the neurodegenerative diseases therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Neurodegenerative Diseases Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for neurodegenerative diseases therapeutics in North America. However, market growth in this region will be slower than the growth of the market in other regions.

The presence of leading players such as Biogen, Johnson & Johnson, and Pfizer and several collaborations among various key players will facilitate the neurodegenerative diseases therapeutics market growth in North America over the forecast period. For instance, in February 2020, Biogen and Sangamo announced a global collaboration to develop gene regulation therapies for AD, PD, neuromuscular, and other neurological diseases.

This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 adversely affected the healthcare sector of various countries in the region. Governments in the region imposed a nationwide lockdown to control the spread of the disease. Moreover, due to the highest number of cases of the disease in the world, the hospitals in the region were running out of space, which significantly reduced the number of other non-emergency healthcare services such as neurodegenerative diseases. However, government initiatives such as mass vaccination drives and other restrictions such as social distancing have helped the regional government to curb the spread of the virus. As a result, the government has removed the lockdowns and relaxed the restrictions, the treatment of piled-up cases of neurodegenerative diseases has started, which will further drive the market for regional neurodegenerative diseases therapeutics during the forecast period.

What are the Revenue-generating Indication Segments in the Neurodegenerative Diseases Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The neurodegenerative diseases therapeutics market share growth by the multiple sclerosis segment will be significant during the forecast period. Researchers are focusing on the innovation of techniques that may help in the identification of risk factors associated with the progression of MS in an individual. The increase in R&D for the development of new drugs for the treatment of MS owing to an increase in the prevalence of MS globally will drive the segment growth in the coming years.

This report provides an accurate prediction of the contribution of all the segments to the growth of the neurodegenerative diseases therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Neurodegenerative Diseases Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 7.98%

Market growth 2022-2026

$ 19.74 billion

Market structure

Concentrated

YoY growth (%)

7.6

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key consumer countries

US, Canada, UK, Germany, Japan, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., Biogen Inc., F. Hoffmann La Roche Ltd., H Lundbeck AS, Mitsubishi Chemical Holdings Corp., Novartis AG, Sanofi, and Teva Pharmaceutical Industries Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Neurodegenerative Diseases Therapeutics Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive neurodegenerative diseases therapeutics market growth during the next five years
  • Precise estimation of the neurodegenerative diseases therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the neurodegenerative diseases therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of neurodegenerative diseases therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Indication
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Indication

    • 5.1 Market segments
      • Exhibit 24: Chart on Indication - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Indication - Market share 2021-2026 (%)
    • 5.2 Comparison by Indication
      • Exhibit 26: Chart on Comparison by Indication
      • Exhibit 27: Data Table on Comparison by Indication
    • 5.3 Multiple sclerosis - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Multiple sclerosis - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Multiple sclerosis - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Multiple sclerosis - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Multiple sclerosis - Year-over-year growth 2021-2026 (%)
    • 5.4 Alzheimers disease - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Alzheimers disease - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Alzheimers disease - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Alzheimers disease - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Alzheimers disease - Year-over-year growth 2021-2026 (%)
    • 5.5 Parkinsons disease - Market size and forecast 2021-2026
      • Exhibit 36: Chart on Parkinsons disease - Market size and forecast 2021-2026 ($ million)
      • Exhibit 37: Data Table on Parkinsons disease - Market size and forecast 2021-2026 ($ million)
      • Exhibit 38: Chart on Parkinsons disease - Year-over-year growth 2021-2026 (%)
      • Exhibit 39: Data Table on Parkinsons disease - Year-over-year growth 2021-2026 (%)
    • 5.6 Huntingtons disease - Market size and forecast 2021-2026
      • Exhibit 40: Chart on Huntingtons disease - Market size and forecast 2021-2026 ($ million)
      • Exhibit 41: Data Table on Huntingtons disease - Market size and forecast 2021-2026 ($ million)
      • Exhibit 42: Chart on Huntingtons disease - Year-over-year growth 2021-2026 (%)
      • Exhibit 43: Data Table on Huntingtons disease - Year-over-year growth 2021-2026 (%)
    • 5.7 Others - Market size and forecast 2021-2026
      • Exhibit 44: Chart on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 45: Data Table on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 46: Chart on Others - Year-over-year growth 2021-2026 (%)
      • Exhibit 47: Data Table on Others - Year-over-year growth 2021-2026 (%)
    • 5.8 Market opportunity by Indication
      • Exhibit 48: Market opportunity by Indication ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 49: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 50: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 51: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 52: Chart on Geographic comparison
      • Exhibit 53: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 54: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 58: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 66: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 70: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Canada - Market size and forecast 2021-2026
      • Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.9 UK - Market size and forecast 2021-2026
      • Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.10 Germany - Market size and forecast 2021-2026
      • Exhibit 82: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 83: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 84: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 85: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.11 Japan - Market size and forecast 2021-2026
      • Exhibit 86: Chart on Japan - Market size and forecast 2021-2026 ($ million)
      • Exhibit 87: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
      • Exhibit 88: Chart on Japan - Year-over-year growth 2021-2026 (%)
      • Exhibit 89: Data Table on Japan - Year-over-year growth 2021-2026 (%)
    • 7.12 China - Market size and forecast 2021-2026
      • Exhibit 90: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 91: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 92: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 93: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.13 Market opportunity by geography
      • Exhibit 94: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 95: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 96: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 97: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 98: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 99: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 100: Matrix on vendor position and classification
            • 10.3 AB Science SA
              • Exhibit 101: AB Science SA - Overview
              • Exhibit 102: AB Science SA - Product / Service
              • Exhibit 103: AB Science SA - Key offerings
            • 10.4 AbbVie Inc.
              • Exhibit 104: AbbVie Inc. - Overview
              • Exhibit 105: AbbVie Inc. - Product / Service
              • Exhibit 106: AbbVie Inc. - Key offerings
            • 10.5 Acadia Pharmaceuticals Inc.
              • Exhibit 107: Acadia Pharmaceuticals Inc. - Overview
              • Exhibit 108: Acadia Pharmaceuticals Inc. - Product / Service
              • Exhibit 109: Acadia Pharmaceuticals Inc. - Key offerings
            • 10.6 Biogen Inc.
              • Exhibit 110: Biogen Inc. - Overview
              • Exhibit 111: Biogen Inc. - Product / Service
              • Exhibit 112: Biogen Inc. - Key offerings
            • 10.7 F. Hoffmann La Roche Ltd.
              • Exhibit 113: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 114: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 115: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 116: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 117: F. Hoffmann La Roche Ltd. - Segment focus
            • 10.8 H Lundbeck AS
              • Exhibit 118: H Lundbeck AS - Overview
              • Exhibit 119: H Lundbeck AS - Product / Service
              • Exhibit 120: H Lundbeck AS - Key offerings
            • 10.9 Mitsubishi Chemical Holdings Corp.
              • Exhibit 121: Mitsubishi Chemical Holdings Corp. - Overview
              • Exhibit 122: Mitsubishi Chemical Holdings Corp. - Business segments
              • Exhibit 123: Mitsubishi Chemical Holdings Corp. - Key offerings
              • Exhibit 124: Mitsubishi Chemical Holdings Corp. - Segment focus
            • 10.10 Novartis AG
              • Exhibit 125: Novartis AG - Overview
              • Exhibit 126: Novartis AG - Business segments
              • Exhibit 127: Novartis AG - Key offerings
              • Exhibit 128: Novartis AG - Segment focus
            • 10.11 Sanofi
              • Exhibit 129: Sanofi - Overview
              • Exhibit 130: Sanofi - Business segments
              • Exhibit 131: Sanofi - Key news
              • Exhibit 132: Sanofi - Key offerings
              • Exhibit 133: Sanofi - Segment focus
            • 10.12 Teva Pharmaceutical Industries Ltd.
              • Exhibit 134: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 135: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 136: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 137: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 138: Teva Pharmaceutical Industries Ltd. - Segment focus

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 139: Inclusions checklist
                • Exhibit 140: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 141: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 142: Research methodology
                • Exhibit 143: Validation techniques employed for market sizing
                • Exhibit 144: Information sources
              • 11.5 List of abbreviations
                • Exhibit 145: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              neurodegenerative diseases therapeutics market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis